Ryan D Maynard
Chief Financial Officer at Foghorn Therapeutics Inc. (FHTX) since February 2026
Ryan D Maynard has filed 16 insider reports with the SEC since July 2021, as director at Iovance Biotherapeutics, Inc. (IOVA), chief Financial Officer at Foghorn Therapeutics Inc. (FHTX) and chief Financial Officer at Cara Therapeutics, Inc. (TVRD). Ryan D Maynard made no open-market purchases or sales in the last 12 months. The latest filing, on June 18, 2026, reports grant or award at Iovance Biotherapeutics, Inc. (IOVA).
- Filings
- 16
- Companies
- 3
- Bought on market
- $50.6K
- Sold on market
- $506K
Companies where Ryan D Maynard is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 7,500 | $50.6K | $503K | $6.75 | $7.48+11% | Jun 18, 2026 | |
| Chief Financial Officersince February 2026 | $1.79 | Feb 24, 2026 | |||||
| Chief Financial Officersince September 2022 | 8,012 | $2,909 | $1.04 | Feb 12, 2024 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Jun 16, 2026IOVASEC Form 4 filed by Director Maynard Ryan DForm 4Grant or award
- Feb 23, 2026FHTXSEC Form 4 filed by Chief Financial Officer Maynard Ryan DForm 4Grant or award
- Feb 23, 2026FHTXRyan D Maynard became an insiderForm 3New insider
- Jun 13, 2025IOVASEC Form 4 filed by Director Maynard Ryan DForm 4Grant or award
- Nov 12, 2024-$503KIOVADirector Maynard Ryan D exercised 50,000 shares at a strike of $7.45 and sold $503,000 worth of shares (50,000 units at $10.06)Form 4Exercise or conversion of a derivativeOpen-market sale
- Nov 12, 2024~$503KIOVARyan D Maynard plans to sell 50,000 shares (~$503K)Form 144Planned sale
- Jun 11, 2024IOVASEC Form 4 filed by Director Maynard Ryan DForm 4Grant or award
- Mar 1, 2024IOVASEC Form 4 filed by Maynard Ryan DForm 4Grant or award
- Feb 8, 2023-$2,909TVRDMaynard Ryan D sold $2,909 worth of shares (5,488 units at $0.53), decreasing direct ownership by 41% to 8,012 unitsForm 4Open-market sale10b5-1 plan
- Feb 1, 2024TVRDMaynard Ryan D was granted 13,500 sharesForm 4Grant or award
- Jun 6, 2023IOVASEC Form 4 filed by Maynard Ryan DForm 4Grant or award
- Sep 12, 2022TVRDSEC Form 4 filed by Maynard Ryan DForm 4Grant or award
- Sep 12, 2022TVRDRyan D Maynard became an insiderForm 3New insider
- Jun 10, 2022IOVASEC Form 4 filed by Maynard Ryan DForm 4Grant or award
- May 31, 2022+$50.6KIOVASEC Form 4: Maynard Ryan D bought $50,588 worth of shares (7,500 units at $6.75)Form 4Open-market purchase
- Jun 29, 2021IOVASEC Form 4 filed by Maynard Ryan DForm 4Grant or award
Compare Ryan D Maynard with
- Ryan D Maynard vs Frederick G Vogt1 shared
- Ryan D Maynard vs Daniel Gordon Kirby1 shared
- Ryan D Maynard vs Corleen M. Roche1 shared
- Ryan D Maynard vs Noah Berkowitz1 shared
- Ryan D Maynard vs Igor Bilinsky1 shared
- Ryan D Maynard vs Raj K. Puri1 shared
Other insiders at the same companies
- Frederick G VogtIOVA
- Daniel Gordon KirbyIOVA
- Corleen M. RocheIOVA
- Noah BerkowitzIOVA
- Igor BilinskyIOVA
- Raj K. PuriIOVA
- Thomas J. Lynch Jr.FHTX
- Stuart DutyFHTX
- Scott BillerFHTX
- Neil GallagherFHTX
- Michael MendelsohnFHTX
- Ian F SmithFHTX
- Simba GillFHTX
- B Lynne ParshallFHTX
- Douglas G. ColeFHTX
- Michael WeiserIOVA
Questions about Ryan D Maynard
- What is Ryan D Maynard's role at Foghorn Therapeutics Inc.?
- Ryan D Maynard reports to the SEC as chief Financial Officer at Foghorn Therapeutics Inc. (FHTX), according to the latest filing on February 24, 2026. Ryan D Maynard has also filed as director at Iovance Biotherapeutics, Inc. (IOVA) and chief Financial Officer at Cara Therapeutics, Inc. (TVRD).
- How many shares does Ryan D Maynard own?
- After the latest filing that states it, Ryan D Maynard directly owned 7,500 shares of Iovance Biotherapeutics, Inc. (IOVA) and 8,012 shares of Cara Therapeutics, Inc. (TVRD). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Ryan D Maynard bought or sold stock recently?
- The most recent open-market purchase was on May 31, 2022: bought 7,500 shares of Iovance Biotherapeutics, Inc. (IOVA) for $50.6K at an average of $6.75. The most recent open-market sale was on November 12, 2024: sold 50,000 shares of Iovance Biotherapeutics, Inc. (IOVA) for $503K at an average of $10.06.
- How do I get alerts when Ryan D Maynard files?
- Follow Ryan D Maynard on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Ryan D Maynard (SEC CIK 0001363984). Totals count each trade once, skipping amendments whose original is on file, from Jul 1, 2021 on. View on SEC EDGAR